Intellectual property issues of immune checkpoint inhibitors

9Citations
Citations of this article
108Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Immune checkpoint inhibitors are drugs that interfere with tumor escape responses. Some members of this class are already approved, and expected to be blockbusters in the future. Many companies have developed patent activities in this field. This article focuses on the patent landscape, and discusses key players and cases related to immune checkpoint inhibitors.

Cite

CITATION STYLE

APA

Storz, U. (2016). Intellectual property issues of immune checkpoint inhibitors. MAbs, 8(1), 10–26. https://doi.org/10.1080/19420862.2015.1107688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free